SLN (Silence Therapeutics Plc American Depository Share) Stock Analysis - AI Report

Silence Therapeutics Plc American Depository Share (SLN) is a publicly traded Healthcare sector company. As of May 20, 2026, SLN trades at $6.24 with a market cap of $294.27M and a P/E ratio of -11.51. SLN moved +7.97% today. Year to date, SLN is +5.23%; over the trailing twelve months it is +21.40%. Its 52-week range spans $1.97 to $20.48. Analyst consensus is buy with an average price target of $27.59. Rallies surfaces SLN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on SLN?

Rallies AI research for SLN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

SLN Key Metrics

Key financial metrics for SLN
MetricValue
Price$6.24
Market Cap$294.27M
P/E Ratio-11.51
EPS$-0.54
Dividend Yield0.00%
52-Week High$20.48
52-Week Low$1.97
Volume158.89K
Avg Volume0
Revenue (TTM)$839.00K
Net Income$-75.04M
Gross Margin79.50%

SLN Analyst Consensus

5 analysts cover SLN: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.59.

Common questions about SLN

What is the AI research view on SLN?
Rallies AI research for SLN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for SLN?
Rallies AI research for SLN combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is SLN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SLN. It does not provide personalized investment advice.
SLN

SLN